You are viewing: Canada Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The Canada Cancer Biomarkers Market was valued at $1075.3 Million in 2026 and projected to reach to $1777 Million by 2031, representing a compound annual growth rate of 8.7%. Canada's cancer biomarkers market is positioned for steady growth at 8.7% CAGR through 2031, driven by advancing healthcare infrastructure, increasing cancer prevalence, and widespread adoption of precision medicine diagnostics.

Canada Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada Cancer Biomarkers Market Trends and Insights

  • This growth trajectory reflects Canada's advancing healthcare infrastructure, increasing cancer prevalence, and rising adoption of precision medicine diagnostics across Canadian healthcare systems.
  • Canada's investment in genomic research and biomarker validation is driving demand for early detection and personalized treatment strategies. The Canadian market benefits from strong regulatory frameworks, including Health Canada's oversight of in vitro diagnostic devices, and collaboration between academic institutions and private sector innovators.
  • Canada's aging population and heightened awareness of cancer screening programs are accelerating biomarker adoption in oncology clinics and diagnostic laboratories.
  • By 2031, Canada is expected to solidify its position as a key market for cancer biomarker technologies in North America, supported by public healthcare funding and private sector expansion..

Key Market Statistics

  • CAGR (2026-2031) 8.7% CAGR
  • Market Size, 2026 ~USD 1075.3 Million
  • Forecast, 2031 ~USD 1777 Million
  • Country Canada

Canada Cancer Biomarkers Market Overview

Market Valuation Growth :

Canada's cancer biomarkers market is valued at $1,075.3 million in 2026 and is projected to reach $1,777.0 million by 2031, demonstrating robust expansion driven by healthcare modernization and increased cancer screening initiatives across Canadian provinces.

Precision Medicine Adoption :

Canadian healthcare systems are increasingly integrating precision medicine diagnostics into oncology treatment protocols, supported by provincial health authority investments and growing physician awareness of biomarker-guided therapeutic approaches.

Rising Cancer Prevalence :

Canada's aging population and lifestyle factors contribute to increasing cancer incidence rates, creating sustained demand for advanced diagnostic biomarkers and early detection solutions across major metropolitan healthcare centers.

Healthcare Infrastructure Investment :

Federal and provincial funding initiatives supporting cancer research and diagnostic innovation are accelerating the adoption of next-generation biomarker testing technologies in Canadian clinical laboratories and oncology centers.

Canada Cancer Biomarkers Market Dynamics

  • Provincial health systems are investing in molecular diagnostics capabilities, while Canadian research institutions collaborate on biomarker discovery and validation initiatives.
  • The market benefits from strong regulatory frameworks and healthcare reimbursement policies supporting innovative diagnostic solutions.
  • Continued integration of genomic testing into standard oncology care pathways will sustain market expansion across Canada's healthcare ecosystem..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Canada's cancer biomarkers market is valued at $1,075.3 million in 2026 and will reach $1,777.0 million by 2031 at an 8.7% CAGR.
      • Canada's aging population and increased cancer screening initiatives are primary drivers of biomarker adoption in Canadian healthcare systems.
      • Health Canada's regulatory framework and collaboration between academic and private sectors strengthen Canada's biomarker innovation ecosystem.
      • By 2031, Canada will represent a significant North American market for precision oncology diagnostics and personalized cancer treatment solutions.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      Canada Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS234.5250.7271.5295.1352.2387.9429.7476.39.8
      DIAGNOSTIC LABORATORIES546.6576.9617.1662.2770.4837.5915.71001.68.4
      OTHER END USERS40.941.742.944.347.649.651.954.34
      RESEARCH AND ACADEMIC INSTITUTES125.4133.4143.7155.4183.7201.3221.9244.79.3
      TOTAL947.51002.61075.311571353.91476.41619.317778.7

      Target Audience

      • Diagnostic Companies & IVD Manufacturers : Evaluate market entry opportunities, competitive positioning, and expansion strategies for cancer biomarker testing platforms and diagnostic assays in the Canadian healthcare market.
      • Healthcare Providers & Hospital Networks : Assess biomarker testing adoption trends, patient demand, and clinical integration opportunities to enhance oncology services and precision medicine capabilities across Canadian healthcare institutions.
      • Pharmaceutical & Biotech Companies : Understand Canadian market dynamics for companion diagnostics, biomarker-driven drug development, and precision oncology partnerships to support clinical trial recruitment and commercialization strategies.
      • Investment & Private Equity Firms : Evaluate investment opportunities in Canadian diagnostic companies, healthcare technology providers, and precision medicine platforms with strong growth potential in the expanding biomarker market.
      • Healthcare Policy & Government Agencies : Inform policy decisions, funding allocations, and healthcare infrastructure investments supporting cancer diagnostics innovation and precision medicine adoption across Canadian provincial health systems.

      Key Companies in the Canada Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Provincial Market Segmentation : Gain detailed insights into cancer biomarker adoption rates across major Canadian provinces including Ontario, Quebec, British Columbia, and Alberta, enabling targeted market entry and partnership strategies.
      • Reimbursement & Regulatory Landscape : Understand Canada's unique healthcare reimbursement policies, provincial formulary listings, and regulatory pathways for biomarker diagnostics, critical for commercialization planning and market access strategies.
      • Competitive Intelligence : Identify leading diagnostic providers, laboratory networks, and healthcare institutions driving biomarker adoption in Canada, with insights into market positioning and partnership opportunities.
      • Growth Driver Analysis : Comprehensive analysis of Canada-specific growth catalysts including aging demographics, cancer screening programs, precision medicine initiatives, and healthcare technology investments shaping market dynamics.
      • Investment & Expansion Planning : Support strategic business decisions with market sizing, growth projections, and opportunity assessment for establishing diagnostic services, partnerships, or distribution networks across Canadian healthcare systems.

      Frequently asked questions

      What is the current size of Canada's cancer biomarkers market?

      Canada's cancer biomarkers market is estimated at $1,075.3 million in 2026.

      What is the projected market size for Canada's cancer biomarkers market by 2031?

      Canada's cancer biomarkers market is forecast to reach $1,777.0 million by 2031.

      What is the growth rate of Canada's cancer biomarkers market?

      Canada's cancer biomarkers market is expected to grow at a compound annual growth rate of 8.7% from 2026 to 2031.

      What factors are driving growth in Canada's cancer biomarkers market?

      Key drivers include Canada's aging population, increased cancer screening programs, precision medicine adoption, and strong regulatory oversight by Health Canada.

      How does Canada's biomarkers market compare to other North American markets?

      Canada represents a significant segment of the North American cancer biomarkers market, supported by robust healthcare infrastructure and genomic research investments.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status